In a hospital room you enter only in a white coverall and double gloves, the monotonous beeping of monitors fills the air. The patient, whose liver is beginning to fail, has dark-red bruises mapping their body; every new needle brings the risk of further uncontrolled bleeding. Doctors know that if they cannot halt the progression of organ failure within the next 48 hours, the chance of survival drops to zero. This is what a severe case of illness caused by the Marburg virus (MARV) looks like—a filovirus related to Ebola.
From lab monkeys to epidemiologists’ handbooks
- The first alarm (1967). In West Germany’s Marburg—and simultaneously at a research institute in Belgrade—dozens of lab workers suddenly developed an unusual hemorrhagic fever. The source was African green monkeys (Chlorocebus aethiops) imported from Uganda for polio-vaccine production; of 31 infected, 7 died.
- African outbreaks. Since the 1970s, sporadic epidemics have returned mainly to Uganda, the DRC, Angola, and in recent years also Guinea and Ghana; fatality rates have ranged from 24% to 88% depending on the viral strain and the availability of intensive care.
Why is the fatality rate so high?
MARV primarily attacks cells of the liver, spleen, and the vascular endothelium. Incubation lasts 2–21 days; onset is sudden, with fever, chills, and severe headache. By day five, diarrhea, vomiting, and a characteristic rash on the torso appear. Internal and external bleeding peaks around day ten, while circulatory collapse leads to multi-organ failure. Supportive care (rehydration, transfusions, electrolyte management) can improve survival odds, but a specific antiviral is still lacking.
Where does the virus “hide” between outbreaks?
Genetic analyses suggest the most likely natural reservoir is fruit bats of the species Rousettus aegyptiacus. In Uganda’s Kitaka and Python caves, researchers have isolated live virus from bat swabs, which helps explain cases of tourists infected after visiting underground colonies. Even so, theories about additional hosts persist, because not every African outbreak has been linked to bats.
Transmission: blood, bodily fluids, and contaminated objects
As with Ebola, close contact with the blood, saliva, vomit, or tissue of an infected person or animal is enough. In field settings, shared razors, ritual preparation of bodies for burial, and discarded protective gear pose a high risk. In hospitals, immediate patient isolation, the use of respirators, and rigorous decontamination procedures are crucial.
Vaccine and treatment research: under way, but no clear winner yet
A recombinant rVSV-platform vaccine (the same technology that succeeded for Ebola) showed 100% protection in macaques in preclinical studies. In 2025, the Sabin Vaccine Institute launched a Phase 2 clinical evaluation in the United States and East Africa; if results are favorable, regulators may consider emergency use during the next outbreak.
Among experimental antivirals, remdesivir has so far generated the most hope—showing 83% survival in cynomolgus macaques when administered early—but robust human data are still lacking.
Potential misuse as a biological weapon
Filoviruses are stable in lyophilized (dried) form and have a low infectious dose when introduced via aerosols, which is why MARV appeared in Biopreparat projects—the secret Soviet program described by defector Ken Alibek. Similar scenarios are also analyzed by the U.S. Center for Civilian Biodefense Studies, although the logistical and technical hurdles are far greater than for anthrax.
Hard lessons from Ebola epidemics led to the creation of WHO rapid mobile laboratories and programs to train local health workers. The same protocols are now deployed for every report of a suspected Marburg case—from isolation tents to satellite links for immediate genomic sequencing.
Interdisciplinary teamwork will be crucial in the next outbreak as well—whether it erupts in Guinea’s rainforest or at a European airport. A globalized world shortens distances not only for people, but also for viruses patiently searching for their opportunity.
Video: How Marburg spreads and what it does to the body
Watch a short animated breakdown of the latest outbreak:
Links to expert sources
- World Health Organization – Marburg virus disease fact sheet World Health Organization
- Centers for Disease Control and Prevention – About Marburg virus cdc.gov
- CDC – History of Marburg outbreaks cdc.gov
- Sabin Vaccine Institute – Phase 2 Marburg vaccine trial announcement Sabin Vaccine Institute
- PubMed – Remdesivir in cynomolgus macaques infected with Marburg virus PubMed
- CNS Non-Proliferation Review – K. Alibek: Biological weapons in the former Soviet Union nonproliferation.org
Robert
I’m interested in technology and history, especially true crime stories. For three years I ran a fact-based portal about modern history, and for a year I co-built a blogging platform where I published dozens of analytical articles. I founded offpitch so that quality content wouldn’t be hidden behind a paywall.
